CENTOGENE , renowned for its expertise in rare and neurodegenerative diseases, has announced the extension of its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs). This collaboration aims to provide rapid and reliable diagnostics for disorders like Fabry disease, Gaucher disease, and Hunter syndrome, ensuring global patient access.
Ian Rentsch, CENTOGENE’s Chief Commercial Officer and General Manager – Pharma, emphasized the significance of accelerating diagnoses for LSD patients worldwide. Leveraging their advanced genomic and multiomic testing portfolio, CENTOGENE aims to improve health outcomes for underserved rare disease communities.
Kim Stratton, CEO of CENTOGENE, highlighted the importance of collaboration, emphasizing partnerships with global players like Takeda and new partners such as Lifera, a biopharmaceutical company owned by the Public Investment Fund (PIF) in Saudi Arabia. This commitment reflects their dedication to delivering life-changing solutions for rare and neurodegenerative disease patients globally.
Originally partnering with Shire Pharmaceuticals in 2015, which was later acquired by Takeda in 2019, CENTOGENE has been instrumental in enhancing early diagnosis of rare genetic diseases. Their mission is to provide data-driven answers, integrating multiomic technologies with the CENTOGENE Biodatabank to guide precision medicine. With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, CENTOGENE’s approach enables rapid and reliable diagnosis, supported by over 30,000 active physicians globally.
The CENTOGENE Biodatabank, comprising over 800,000 patients from 120 countries, has contributed to over 285 peer-reviewed publications, generating novel insights. Through collaborations with over 50 pharma partners, CENTOGENE accelerates drug discovery, development, and commercialization, offering insight reports and licenses to advance the fight against rare and neurodegenerative diseases.
CENTOGENE’s extended partnership with Takeda underscores their commitment to providing life-changing diagnostics and advancing research in rare and neurodegenerative diseases, ultimately aiming for a world healed of these conditions.